Should You Invest in Mirum Pharmaceuticals (MIRM)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except fixed income outside the U.S. posted positive returns. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, TimesSquare Capital U.S. Small Cap Growth Strategy highlighted stocks such as Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM). Headquartered in Foster City, California, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a biopharmaceutical company. The one-month return of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) was 15.54%, and its shares gained 79.65% of their value over the last 52 weeks. On January 5, 2026, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) stock closed at $75.56 per share, with a market capitalization of $3.905 billion.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the following regarding Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in its third quarter 2025 investor letter:

"New to the strategy this quarter was Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a commercial-stage biopharma developer of liver disease treatments. Miram is developing several new applications for its treatments, including expanding its flagship Livmarli to treat a third indication."

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 42 hedge fund portfolios held Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) at the end of the third quarter, up from 31 in the previous quarter. In Q3 2025, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported revenue of $133 million, representing a nearly 50% year-over-year increase. While we acknowledge the potential of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and shared the list of best biotech stocks to buy according to Wall Street analysts. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.